“The following toxicology study was conducted to evaluate the safety of PRGN-2012 following SC administration in WT mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Why that species
Mouse used for immunogenicity/safety; reviewer notes murine antigen processing likely differs from human T-cell recognition
“The dose level assessed in this non-GLP toxicology study provides a 5-fold safety factor for the clinical dose level with the caveat that the processing and binding sequences in wildtype mice is likely different than the peptides recognized by human T cells .”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Surrogate molecule
No surrogate; nonclinical lot PRGN-2012 of clinical vector, differing only in scale and standardized manufacturing
“The differences made between PRGN-2012 nonclinical lot and PAPZIMEOS are scaling and the use of standardized manufacturing for PAPZIMEOS.”
✓ VerifiedFDA summary basis for approval, p. 13Source ↗